Incyte Corporation

This study is testing whether adding a new immunotherapy drug called retifanlimab to standard chemotherapy helps people with advanced lung cancer live longer or slows the cancer's growth better than chemotherapy alone. It involved 583 adults with newly diagnosed, advanced non-sma…

This study allows people who were already receiving itacitinib in previous clinical trials to continue taking the medication. It's for adults with myelofibrosis, chronic graft-versus-host disease, or lung transplant complications who were benefiting from the drug in earlier studi…

This study is testing a new oral drug called INCB099280 in people with advanced solid tumors who have not yet received immunotherapy. The main goals are to see if the drug is safe and if it can shrink tumors. It is for patients with specific cancers like liver cancer, melanoma, l…

This early-stage study is testing the safety and best dose of a new drug called INCB040093, both alone and combined with another drug called itacitinib. It is for adults with B-cell blood cancers (like certain lymphomas and leukemias) that have come back or didn't respond to prio…

This study is testing an immunotherapy drug called retifanlimab, given alone or with other drugs, for women with advanced endometrial (uterine) cancer that has continued to grow despite standard platinum-based chemotherapy. The main goal is to see if the treatment can shrink tumo…

This large, late-stage study is testing whether adding two newer drugs (tafasitamab and lenalidomide) to the standard R-CHOP chemotherapy helps people with newly diagnosed, high-risk diffuse large B-cell lymphoma (DLBCL) live longer without their cancer getting worse. It will com…

This study is testing a new drug called INCB000928 to see if it can help people with a serious bone marrow cancer called myelofibrosis who have severe anemia. The drug will be tested alone and in combination with an existing medication, ruxolitinib. The main goals are to find a s…

This study is testing whether an oral medication called povorcitinib can help restore skin color in adults with nonsegmental vitiligo. About 450 participants will take either the drug or a placebo for 52 weeks to see how well it works on facial and body patches. Researchers will …

This study is testing whether an investigational drug called axatilimab works better than the best currently available treatments for chronic graft-versus-host disease (cGVHD). It is for patients aged 12 and older whose cGVHD has not improved after at least two prior drug treatme…

This study is testing an investigational drug called INCB099280 in people with advanced squamous cell carcinoma, a type of skin cancer that has spread or cannot be treated with surgery or radiation. The main goals are to see if the drug is safe and if it can shrink tumors. It inv…

This study is testing the safety and effectiveness of a two-drug combination (tafasitamab plus lenalidomide) for adults with an aggressive type of blood cancer called diffuse large B-cell lymphoma (DLBCL). It is for people whose cancer has returned or did not respond to 1 to 3 pr…

This early-stage study is testing a new drug called INCB177054, given alone or with an immunotherapy drug, in people with advanced solid tumors that have spread or cannot be cured by surgery. The main goals are to find a safe dose and see if the treatment can shrink tumors. It is…

This is a first-in-human study to test the safety and initial effectiveness of a new drug called INCB186748. It is for adults with advanced or metastatic solid tumors that have a specific genetic change called a KRAS G12D mutation. The main goals are to find a safe dose and see h…

This early-stage study is testing a new drug called INCB057643, both alone and in combination with an existing drug (ruxolitinib), in adults with advanced blood cancers like myelofibrosis. The main goal is to check if the treatment is safe and tolerable. Researchers will also loo…

This study follows 617 people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition, to check the long-term safety and effectiveness of the drug povorcitinib. Participants have already completed 54 weeks of treatment in previous studies and will continue…

This study is testing a new, modified dosing schedule for a drug combination (tafasitamab plus lenalidomide) in patients whose diffuse large B-cell lymphoma has come back or hasn't responded to prior treatments. The main goals are to check the safety of this new schedule and see …

This study allows people with B-cell cancers who are already taking the drug parsaclisib in another company-sponsored trial to continue receiving it. It is for patients who are benefiting from the treatment but cannot get it outside of a research study. The main goal is to monito…

This Phase 3 trial is testing whether an oral medication called povorcitinib can help restore skin color in adults with nonsegmental vitiligo. Over 450 participants will take either the drug or a placebo for 52 weeks to see how well it reduces white patches on the face and body a…

This study allows patients who were already taking the drug ruxolitinib in a previous cancer trial to continue receiving it, along with their other cancer treatments, if they are benefiting. It's for people with pancreatic, colorectal, breast, or lung cancer who are doing well on…

This large, late-stage study is testing if adding a new drug, tafasitamab, to a standard two-drug regimen (lenalidomide + rituximab) works better for controlling two types of slow-growing lymphoma that have returned or stopped responding to prior treatment. It involves 654 patien…